<DOC>
	<DOCNO>NCT00002323</DOCNO>
	<brief_summary>PRIMARY : To compare virologic activity ( quantitative RNA PCR , quantitative PBMC ) combination nevirapine zidovudine ( AZT ) versus AZT alone 3 6 month treatment . To compare effect two regimen CD4 T-cell count percentage . SECONDARY : To compare evaluate marker immunologic virologic activity patient receive nevirapine/AZT versus AZT alone . To compare effect two regimen clinical sign symptom . To evaluate safety tolerance two regimen .</brief_summary>
	<brief_title>A Multi-Center , Placebo-Controlled , Double-Blind , Randomized Trial Comparing Virologic Immunologic Activities 400 Mg Nevirapine Combination With Zidovudine Versus Zidovudine Alone Asymptomatic HIV-1 Infected Patients With 4-12 Months Prior Zidovudine Therapy 200-500 CD4+ Cell</brief_title>
	<detailed_description>Patients receive combination nevirapine/AZT AZT alone . Patients evaluate virologic immunologic activity 3 6 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis ( trimethoprimsulfamethoxazole , dapsone , aerosolized pentamidine ) , discretion investigator . Antifungal prophylaxis oral fluconazole ketoconazole . Antiviral prophylaxis herpes simplex virus &lt; = 1000 mg/day oral acyclovir . Dilantin prevention treatment seizure . Patients must : Asymptomatic HIV infection . CD4 count 200500 cells/mm3 . No prior AIDS . No history active HIVrelated thrush , vaginal candidiasis , zoster ( shingle ) , excessive weight loss , persistent fever , diarrhea . Tolerated 500600 mg AZT daily least 4 month 12 month immediately prior study entry . Consent parent guardian le 18 year age . NOTE : Patients may coenroll another protocol involve investigational drug biologics . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy limit cutaneous basal cell carcinoma . Psychiatric condition sufficient impair study compliance . Concurrent Medication : Excluded : Systemic glucocorticoid steroid hormone . Dicumarol , warfarin , anticoagulant medication . Cimetidine . Tolbutamide . Doxycycline . Chloramphenicol . Phenobarbital barbiturates . Foscarnet . Erythromycin . Amoxicillinclavulanate ( Augmentin ) . Ticarcillin clavulanate . Biologic response modifier ( alpha interferon , IL2 , immune modulators ) . Any investigational drug study drug . Patients follow prior condition exclude : History clinically important disease HIV infection , may put patient risk participation study . Prior Medication : Excluded : Antiretroviral medication AZT . Excluded within 4 week prior study entry : Immunosuppressive cytotoxic drug experimental drug . Systemic glucocorticoid steroid hormone . Dicumarol , warfarin , anticoagulant medication . Cimetidine . Tolbutamide . Doxycycline . Chloramphenicol . Phenobarbital barbiturates . Foscarnet . Erythromycin . Amoxicillinclavulanate ( augmentin ) . Ticarcillin clavulanate . Biologic response modifier ( alpha interferon , IL2 , immune modulators ) . Required : AZT 500600 mg/day least 4 month 12 month immediately precede study entry . Chronic use alcohol drug sufficient impair study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
</DOC>